NRX Pharmaceuticals, Inc. Logo

NRX Pharmaceuticals, Inc.

Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.

NRXP | US

Overview

Corporate Details

ISIN(s):
US0894821034 (+2 more)
LEI:
Country:
United States of America
Address:
1201 ORANGE STREET, 19801 WILMINGTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system (CNS) disorders. The company is focused on addressing the high unmet medical need for treatments for severe bipolar depression and Post-Traumatic Stress Disorder (PTSD), particularly in patients with suicidal ideation. Its lead candidate, NRX-101, is the first investigational oral medication in FDA trials for suicidal bipolar depression and has received Fast Track and Breakthrough Therapy designations. The company's scientific platform is based on targeting the brain's NMDA receptor with a non-hallucinogenic, non-addictive approach. Its pipeline also includes KETAFREE™, a preservative-free ketamine product for suicidal depression.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all NRX Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NRX Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NRX Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Grifols S.A. Logo
Leading producer of plasma-derived medicines for patients with rare and chronic diseases.
Spain GRF
Grifols SA Logo
Develops plasma-derived medicines and transfusion solutions for rare and chronic conditions.
United States of America GRFS
Grindeks Logo
Develops & manufactures pharmaceuticals for cardiovascular, CNS, cancer, and diabetes globally.
Latvia GRD1R
GSK plc Logo
Develops specialty medicines and vaccines to prevent and treat a range of global diseases.
United States of America GSK
GT Biopharma, Inc. Logo
Develops TriKE® immunotherapies engaging NK cells to treat hematologic and solid tumor cancers.
United States of America GTBP
Guardant Health, Inc. Logo
Develops liquid biopsies for cancer detection, monitoring, and personalized treatment guidance.
United States of America GH
Guard Therapeutics International AB Logo
Clinical-stage biotech developing drugs to prevent acute kidney injury during open-heart surgery.
Sweden GUARD
Develops research antibodies and distributes scientific instruments for life science researchers.
South Korea 036180
GYRE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing novel drugs for liver fibrosis and pneumoconiosis.
United States of America GYRE
Haleon plc Logo
A consumer healthcare leader offering trusted OTC brands for everyday health and wellness.
United States of America HLN

Talk to a Data Expert

Have a question? We'll get back to you promptly.